{"analyses":[{"ciLowerLimit":"0.46","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.04","estimateComment":"Cox proportional hazard analysis stratified (Arm A vs. Arm B) by factors recorded in IXRS data including presence of deletion 17 p (yes / no), ECOG (0-1/2), # of prior therapies (1-3/4+).","groupDescription":"Analysis stratified by factors recorded in IXRS data including presence of deletion 17 p (yes / no), ECOG (0-1/2), # of prior therapies (1-3/4+).","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0783","paramType":"Hazard Ratio (HR)","paramValue":"0.69","statisticalComment":"Log-Rank Analysis stratified by factors recorded in IXRS data: presence of deletion 17 p (yes / no), ECOG (0-1/2), # of prior therapies (1-3/4+).","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Kaplan-Meier estimate for median OS and 95% CIs were not reached.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Kaplan-Meier estimate for median OS and 95% CIs were not reached.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"155"}],"units":"Participants"}],"description":"Overall Survival (OS) was based on data cutoff date of 03Sep2021","dispersionType":"95% Confidence Interval","groups":[{"description":"Acalabrutinib 100 mg orally twice a day","id":"OG000","title":"Arm A: Acalabrutinib Monotherapy"},{"description":"Idelalisib+Rituximab or Bendamustine + Retuximab","id":"OG001","title":"Arm B: Investigator's Choice"}],"paramType":"MEDIAN","populationDescription":"Intent-to treat (ITT) population including all randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization date to date of death due to any cause, or date of study discontinuation, or date of data cutoff on 03Sep2021, whichever came first until 54 months of follow-up.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}